Story thread · 2 reports / 1 sources
CSL plunges to $3.7b loss as weak US vaccine rates hamper recovery
afr.com · 10h · first report
The struggling healthcare giant reported a sharp drop in sales at its Vifor kidney business, but expects underlying earnings to increase 5 per cent this year.
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.